REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.49
+0.03 (0.35%)
Mar 26, 2026, 12:07 PM EDT - Market open
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$459,410
Profits / Employee
-$522,582
Market Cap
438.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | 18 | 5.10% |
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Ginkgo Bioworks Holdings | 485 |
| Maravai LifeSciences Holdings | 435 |
| Absci | 140 |
| Invivyd | 122 |
| Verastem | 102 |
| Aclaris Therapeutics | 73 |
| Assembly Biosciences | 73 |
RGNX News
- 14 days ago - Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Benzinga
- 15 days ago - Regenxbio's Duchenne gene therapy shows improved muscle function in trial - Reuters
- 15 days ago - REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 19 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 20 days ago - REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - PRNewsWire
- 21 days ago - REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 22 days ago - REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire